Literature DB >> 25230055

Assessment of the effective absorbed dose of 4-benzyl-1-(3-[125I]-iodobenzylsulfonyl)piperidine in humans on the basis of biodistribution data of rats.

Masoud Sadeghzadeh1, Saeed Shanehsazzadeh, Afsaneh Lahooti.   

Abstract

OBJECTIVES: The aim of this study was to estimate the effective absorbed radiation dose to human organs following promising in-vivo results of intravenous administration of 4-benzyl-1-(3-[125I]-iodobenzylsulfonyl)piperidine (4-B-[125I]-IBSP) using normal biodistribution data obtained from rats.
MATERIALS AND METHODS: Five rats were killed at exact time intervals and the percentage of injected dose per gram of each organ was measured by direct counting from rat data. The medical internal radiation dose formulation was applied to extrapolate from rats to humans and to project the absorbed radiation dose for various human organs.
RESULTS: The dose estimation shows that the organs that received the highest absorbed dose were the brain, bone surface, and red marrow (10.51, 0.69, and 0.08 μGy/MBq, respectively). Our prediction shows that a 185 MBq injection of 4-B-[125I]-IBSP into humans might result in an estimated absorbed dose of 49.39 μGy for the whole body. The highest effective absorbed dose for 4-B-[125I]-IBSP was in the brain (19.4 μSv) and the organs that received the next highest doses were the bone surface, red marrow, muscle, and thyroid, with magnitudes of 15.27, 1.81, 0.15, and 0.10 μSv, respectively.
CONCLUSION: The results of this study suggest that 4-B-[125I]-IBSP is a suitable and safe candidate in clinical studies and in lung malignancies.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25230055     DOI: 10.1097/MNM.0000000000000210

Source DB:  PubMed          Journal:  Nucl Med Commun        ISSN: 0143-3636            Impact factor:   1.690


  3 in total

1.  Preparation, Biological Evaluation and Dosimetry Studies of 175Yb-Bis-Phosphonates for Palliative Treatment of Bone Pain.

Authors:  Ashraf Fakhari; Amir R Jalilian; Hassan Yousefnia; Saeed Shanehsazzadeh; Ali Bahrami Samani; Fariba Johari Daha; Mehdi Shafiee Ardestani; Ali Khalaj
Journal:  Mol Imaging Radionucl Ther       Date:  2015-10-05

2.  Development of 153Sm-DTPA-SPION as a theranostic dual contrast agents in SPECT/MRI.

Authors:  Amir Gholami; Seyyed Hossein Mousavie Anijdan
Journal:  Iran J Basic Med Sci       Date:  2016-10       Impact factor: 2.699

3.  Preclinical Evaluation of 68Ga-MAA from Commercial Available 99mTc-MAA Kit.

Authors:  Saeed Shanehsazzadeh; Amir Reza Jalilian; Afsaneh Lahooti; Parham Geramifar; Davood Beiki; Hassan Yousefnia; Amir Rabiee; Mohammad Mazidi; Seyedeh Fatemeh Mirshojaei; Stephan Maus
Journal:  Iran J Pharm Res       Date:  2017       Impact factor: 1.696

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.